Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 708

1.

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study.

Azar ST, Hantash HA, Jambart S, El-Zaheri MM, Rachoin R, Chalfoun A, Lahoud L, Okkeh O, Bramlage P, Brudi P, Ambegaonkar BM.

Vasc Health Risk Manag. 2014 May 7;10:225-35. doi: 10.2147/VHRM.S57194. eCollection 2014.

PMID:
24872710
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR.

Vasc Health Risk Manag. 2014 Apr 25;10:237-46. doi: 10.2147/VHRM.S54886. eCollection 2014.

PMID:
24851051
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).

Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1298-306. doi: 10.1161/ATVBAHA.113.302926. Epub 2014 Apr 17.

PMID:
24743431
[PubMed - indexed for MEDLINE]
4.

Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.

Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M; CRUCIAL trial investigators.

Vasc Health Risk Manag. 2014 Mar 26;10:145-56. doi: 10.2147/VHRM.S54586. eCollection 2014.

PMID:
24707184
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).

Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ.

Am J Cardiol. 2014 May 15;113(10):1593-8. doi: 10.1016/j.amjcard.2014.02.011. Epub 2014 Mar 1.

PMID:
24666618
[PubMed - indexed for MEDLINE]
6.

Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).

Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD.

Am J Cardiol. 2014 Apr 15;113(8):1378-82. doi: 10.1016/j.amjcard.2014.01.414. Epub 2014 Feb 1.

PMID:
24582532
[PubMed - indexed for MEDLINE]
7.

Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).

Kaul U, Varma J, Kahali D, Hiremath MS, Dani S, Dalal J, Ramchandran P, Rane R, Barkate H, Jindal C.

J Assoc Physicians India. 2013 Feb;61(2):97-101.

PMID:
24471247
[PubMed - indexed for MEDLINE]
8.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

PMID:
24265554
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.

Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, Messerli FH; Treating to New Targets Steering Committee and Investigators.

Am J Med. 2014 Jan;127(1):71-81.e1. doi: 10.1016/j.amjmed.2013.07.038. Epub 2013 Nov 7.

PMID:
24210549
[PubMed - indexed for MEDLINE]
10.

Statins decrease mean platelet volume irrespective of cholesterol lowering effect.

Sivri N, Tekin G, Yalta K, Aksoy Y, Senen K, Yetkin E.

Kardiol Pol. 2013;71(10):1042-7. doi: 10.5603/KP.2013.0259.

PMID:
24197585
[PubMed - indexed for MEDLINE]
11.

[A multi-device approach to an unusual case of left main thrombosis: when manual thrombectomy is not enough].

Picchi A, Calabria P, Micheli A, Limbruno U.

G Ital Cardiol (Rome). 2013 Oct;14(10):677-80. doi: 10.1714/1335.14835. Italian.

PMID:
24121893
[PubMed - indexed for MEDLINE]
12.

Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).

Liu PY, Lin LY, Lin HJ, Hsia CH, Hung YR, Yeh HI, Wu TC, Chen JY, Chien KL, Chen JW.

PLoS One. 2013 Oct 1;8(10):e76298. doi: 10.1371/journal.pone.0076298. eCollection 2013.

PMID:
24098467
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].

Gao J, Cong HL, Mao YM, Liu Y, Zhang N, Chen Q, Liu T, Cui R.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013 Oct;30(5):553-8. doi: 10.3760/cma.j.issn.1003-9406.2013.05.010. Chinese.

PMID:
24078569
[PubMed - indexed for MEDLINE]
14.

C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.

Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ.

Circulation. 2013 Nov 26;128(22):2395-403. doi: 10.1161/CIRCULATIONAHA.113.004243. Epub 2013 Sep 16.

PMID:
24043299
[PubMed - indexed for MEDLINE]
15.

Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.

Qi Y, Liu J, Ma C, Wang W, Liu X, Wang M, Lv Q, Sun J, Liu J, Li Y, Zhao D.

J Lipid Res. 2013 Nov;54(11):3189-97. doi: 10.1194/jlr.P040360. Epub 2013 Aug 20.

PMID:
23964121
[PubMed - indexed for MEDLINE]
16.

Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.

Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators.

J Am Coll Cardiol. 2013 Aug 20;62(8):717-29. doi: 10.1016/j.jacc.2013.02.098.

PMID:
23948514
[PubMed - indexed for MEDLINE]
Free Article
17.

NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.

Satoh M, Tabuchi T, Itoh T, Nakamura M.

Clin Sci (Lond). 2014 Feb;126(3):233-41. doi: 10.1042/CS20130043.

PMID:
23944632
[PubMed - indexed for MEDLINE]
18.

Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.

Kang S, Liu Y, Liu XB.

Clin Ther. 2013 Aug;35(8):1125-36. doi: 10.1016/j.clinthera.2013.06.006. Epub 2013 Aug 7. Review.

PMID:
23932462
[PubMed - indexed for MEDLINE]
Free Article
19.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.

J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.

PMID:
23890516
[PubMed - indexed for MEDLINE]
20.

Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.

Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ.

Eur Heart J. 2013 Nov;34(41):3182-90. doi: 10.1093/eurheartj/eht260. Epub 2013 Jul 25.

PMID:
23886915
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk